Antibiotic resistance of urinary tract pathogens has increased worldwide. Our aim was to provide information regarding resistance patterns of Escherichia coli in urinary tract infections (UTIs) and E. coli bacteraemia in Denmark. The overall resistance ranged from: ampicillin 20-47%, mecillinam 0-7%, trimethoprim 10-28%, sulfamethizole 22-47% and nitrofurantoin 0-3%. In strains with sulfamethizole MICs > 2048 mg/L, 97% carried sulI, sulII or both genes, with sulII being the most common. Among the sulI gene-positive strains, 96% were intI 1 gene positive.
Introduction
The choice of empirical treatment for uncomplicated urinary tract infections (UTIs) is debated, because 20-50% of Escherichia coli are now resistant to some of the first-line antibiotics. The present study was designed: (i) to determine the current resistance pattern among E. coli UTIs in general practice, hospitalized patients and E. coli bacteraemia originating from community-acquired UTIs; (ii) to look at coresistance; and (iii) to determine the distribution of sul genes in Danish isolates. In Denmark the recommended first-line treatment for uncomplicated UTI is sulfamethizole.
Materials and methods

Bacterial strains
Group I. Forty-four general practitioners in Roskilde County each received 20 Uricult Trio dipslides (Orion Diagnostica, Espoo, Finland), from February to April 1997, on which to perform consecutive urinary culturing on all patients with symptoms of UTI. The UTI was defined as uncomplicated if all of the following criteria were fulfilled: (i) female gender; (ii) age 14-60 years; (iii) symptoms: dysuria, frequency, suprapubic pain, absence of loin pain, absence of fever; (iv) not pregnant; (v) no known deformity in the urinary tract; and (vi) less than three UTIs in the past year. All other UTIs were classified as complicated. 1 All dipslides, including those with ≤10 5 cfu/ mL, were sent to Statens Serum Institute, Department of Microbiological R & D.
Group II. The Department of Clinical Biochemistry at the county hospital in Roskilde (RAS) performed (from April to June 1999) all urinalyses at the hospital and forwarded cultivated consecutive strains from hospital-acquired UTIs (defined as UTI starting >3 days after admission).
Group III. A selection of E. coli bacteraemia strains from RAS tested at the Department of Clinical Microbiology (DCM) at Statens Serum Institute (1997-1999) was carried out according to the following criteria: probable focus in the urinary tract and infection acquired in the community (bacteraemia <3 days after hospitalization).
Identification
Group I: dipslides were inspected visually, according to the manufacturer's manual, and the cfu/mL was determined on CLED agar, MacConkey agar and E. coli agar (β-glucuronidase). Only dipslides with ≥10 3 cfu/mL were processed further, and were cultured on differential media. Identification for groups II and III relied on the identification originally performed at RAS and DCM, respectively. 
MIC determination
MICs were obtained by the agar dilution method according to the NCCLS, 2 using Mueller-Hinton II agar (Becton Dickinson). The breakpoints used for Enterobacteriaceae were as defined by the NCCLS. Amplification (GeneAmp PCR System 2400; Perkin Elmer) was carried out by heating for 5 min at 94°C, followed by 30 cycles of 94°C for 15 s, 69°C for 30 s and 72°C for 60 s, followed by one cycle at 72°C for 7 min. Gel electrophoresis was carried out on 2% w/v agarose gel (1% NuSieve GTG agarose and 1% SeaKem GTG agarose) (FMC BioProducts, Rockland, ME, USA). D-15 DNA Marker (Novex, San Diego, CA, USA) was used as a marker and E. coli NCTC 50001, E. coli NCTC 50020 and a susceptible strain from our own collection were used as controls in each PCR run.
Statistical methods
Fisher's exact test was used, with P < 0.05 considered as significant.
Results and discussion
Group I: of 188 samples (94% ≥10 5 cfu/mL) 37% were from uncomplicated UTIs (81% E. coli) and 63% were isolated from complicated UTIs (68% E. coli). Group II: we received 137 identified strains from RAS (55% E. coli). Group III: we found 74 E. coli isolates that fulfilled the criteria. Table 1 shows the distribution of resistance in E. coli. Resistance to ampicillin, mecillinam and sulfamethizole was significantly higher in the hospital than in the community E. coli in total. Trimethoprim and nitrofurantoin resistance were not significantly different in the three strain collections. Trimethoprim and sulfamethizole resistance among the complicated UTIs were significantly higher compared with the uncomplicated UTIs. Compared with a Danish study in general practice published in 1980, 4 our data show a significant increase in the ampicillin and trimethoprim resistance, a moderate increase in the sulphonamide resistance and a decrease or status quo in the mecillinam and nitrofurantoin resistance in general practice in Denmark. Data from others with respect to uncomplicated UTIs, 5 and in general practice in total, 6 support our findings. The high incidence of resistance among hospital UTIs and bacteraemia resembles that from a British survey. 7 Table 1 . Resistance in E. coli according to NCCLS breakpoints a Significantly different from the value in community-acquired UTI (total) (P < 0.05). b Significantly different from the value in community-acquired uncomplicated UTI (P < 0.05). c Significantly different from the value in community-acquired complicated UTI (P < 0.05).
Community-acquired UTI Antibiotic (breakpoint) For strains resistant to either ampicillin, sulphonamide or trimethoprim, resistance to another antibiotic (i.e. co-resistance) was seen in 45-86%. In contrast, in strains susceptible to these antibiotics, co-resistance was seen in only 5-26% (P < 0.05).
All 292 E. coli were tested for sul and int genes by the multiplex PCR assay (Figure 1 ). Strains with MICs ranging from 8 to 512 mg/L (n = 184) did not possess any sul genes. One E. coli with an MIC of 512 mg/L was sulI and sulII positive. Among the 107 E. coli with MICs > 2048 mg/L, the distribution of sul genes was as follows: 54 sulII positive, 30 sulI positive, 20 sulI and sulII positive; three strains lacked any of these genes. Of the 51 sulI-positive isolates, 49 carried the integron-associated integrase gene IntI 1. The genetics of clinical sulphonamide-resistant E. coli has been published recently, 8 and the distribution among strains with MICs ≥ 512 mg/L resembles what we have found.
Resistance genes conferring ampicillin, trimethoprim and sulphonamide resistance are linked on R-plasmids that can transfer resistance between bacteria. 9 In E. coli, the sulphonamide resistance conferred by sulI (on integron 1) and sulII genes has been shown to transfer between E. coli in in vitro and in vivo experiments. 8, 10 The common opinion in Denmark that sulphonamides and ampicillin are safe to use for empirical treatment of UTIs has to be re-evaluated in light of the resistance level and the risk of selecting for resistant bacterial populations.
